Faatz Henrik, Hattenbach Lars-Olof, Krohne Tim U, Priglinger Siegfried G, Lommatzsch Albrecht
Augenzentrum am St. Franziskus-Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland.
Achim Wessing Institut f. Ophthalmologische Diagnostik, Universitätsklinikum Essen-Duisburg, Essen, Deutschland.
Ophthalmologie. 2024 Jun;121(6):470-475. doi: 10.1007/s00347-024-02042-4. Epub 2024 May 29.
Vitreomacular traction is a tractive foveolar adhesion of the posterior vitreous limiting membrane, resulting in pathological structural alterations of the vitreomacular interface. This must be differentiated from physiological vitreomacular adhesion, which exhibits a completely preserved foveolar depression. Symptoms depend on the severity of the macular changes and typically include reduced visual acuity, reading problems and metamorphopsia. High-resolution spectral domain optical coherence tomography (SDOCT) imaging enables classification of the sometimes only subtle morphological changes. If pronounced vitreomacular traction is accompanied by epiretinal gliosis and alterations to the outer retina, it is referred to as a vitreomacular traction syndrome. Vitreomacular traction has a high probability of spontaneous resolution within 12 months. Therefore, treatment should only be carried out in cases of undue suffering of the patient and with symptoms during bilateral vision and a lack of spontaneous resolution. In addition to pars plana vitrectomy, alternative treatment options, such as intravitreal injection of ocriplasmin and pneumatic vitreolysis are discussed for vitreomacular traction with an associated macular hole; however, ocriplasmin is no longer available in Germany. The best anatomical results in comparative investigations were achieved by vitrectomy. Pneumatic vitreolysis is controversially discussed due to the increased risk of retinal tears. In one of the current S1 guidelines of the German ophthalmological societies evidence-based recommendations for the diagnostics and treatment of vitreomacular traction are summarized.
玻璃体黄斑牵引是指玻璃体后界膜对黄斑中心凹的牵引性粘连,导致玻璃体黄斑界面出现病理性结构改变。这必须与生理性玻璃体黄斑粘连相鉴别,生理性玻璃体黄斑粘连时黄斑中心凹形态完全正常。症状取决于黄斑病变的严重程度,通常包括视力下降、阅读困难和视物变形。高分辨率光谱域光学相干断层扫描(SDOCT)成像能够对有时仅很细微的形态学改变进行分类。如果明显的玻璃体黄斑牵引伴有视网膜前胶质增生和外层视网膜改变,则称为玻璃体黄斑牵引综合征。玻璃体黄斑牵引很有可能在12个月内自行缓解。因此,仅在患者有过度痛苦、双眼视力出现症状且未自行缓解的情况下才应进行治疗。除了玻璃体切割术,对于伴有黄斑裂孔的玻璃体黄斑牵引,还讨论了其他治疗选择,如玻璃体内注射奥克纤溶酶和气体性玻璃体溶解术;然而,奥克纤溶酶在德国已不再可用。在比较研究中,玻璃体切除术取得了最佳的解剖学效果。由于视网膜裂孔风险增加,气体性玻璃体溶解术存在争议。德国眼科学会当前的一项S1指南总结了基于证据的玻璃体黄斑牵引诊断和治疗建议。